If you have been reading about synaptogenesis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-02. Numbers and descriptions here follow the published literature rather than marketing material.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
== Precautions == Protactinium is both toxic and highly radioactive; thus, it is handled exclusively in a sealed glove box. Its major isotope 231Pa has a specific activity of 0.048 curies (1.8 GBq) per gram and primarily emits alpha particles, which can be stopped by a thin layer of any material. However, it slowly decays into 227Ac, and then follows the more rapid actinium series, making its total activity (alpha, beta, and gamma) greater than one would calculate from that figure. As protactinium is present in small amounts in most natural products and materials, it is ingested with food or water and inhaled with air. Only about 0.05% of ingested protactinium is absorbed into the blood and the remainder is excreted. From the blood, about 40% of the protactinium deposits in the bones, about 15% goes to the liver, 2% to the kidneys, and the rest leaves the body. The biological half-life of protactinium is about 50 years in the bones, whereas its biological half-life in other organs has a fast and slow component. For example, 70% of the protactinium in the liver has a biological half-life of 10 days, and the remaining 30% for 60 days. The corresponding values for kidneys are 20% (10 days) and 80% (60 days). In each affected organ, protactinium promotes cancer via its radioactivity. The maximum amount of Pa allowed in the human body is 0.03 μCi (1.1 kBq), which corresponds to 0.5 micrograms of 231Pa. The maximum allowed concentrations of 231Pa in the air in Germany is 3×10−4 Bq/m3.
Certain serotonergic psychedelics and related non-hallucinogenic drugs, acting as serotonin 5-HT2A receptor agonists, have been reported to have mild stimulant and/or "psychic energizing" (i.e., acute antidepressant) effects, both in animals and humans. These effects are often present at low or sub-hallucinogenic doses. Psychedelics are also known to promote wakefulness or cause insomnia. Psychedelic and related drugs that have been reported to produce stimulant effects include the phenethylamines 2,5-DMA (DOH), DOM, DOET, DOPR, DON, MTFEM, Ariadne (4C-DOM; BL-3912; Dimoxamine), 2C-B, 2C-D, 2C-G-N, and ASR-2001 (2CB-5PrO), and the tryptamines 5-MeO-DiPT and 5-MeO-MiPT, among others. The lysergamide LSD has also been reported to have mild stimulant effects. Conversely, psilocybin does not seem to produce the same stimulant effects. The non-hallucinogenic Ariadne was under development as a potential pharmaceutical drug to take advantage of such effects in the treatment of conditions like depression in the 1970s, and reached phase 3 clinical trials for such indications, but was shelved reportedly for strategic economic reasons. ASR-2001, which is likewise non-hallucinogenic, is under development for use as a stimulant-like medication for treatment of psychiatric disorders. Serotonin 5-HT2A receptor agonists have been found to increase dopamine levels in brain areas like the frontal cortex, striatum, and nucleus accumbens in animal studies.
Ian Buruma, author and journalist; board member of Human Rights in China; fellow of European Council of Foreign Relations; journalist for The New York Review of Books and has written for The Guardian; held fellowships at Wissenschaftskolleg and at Woodrow Wilson International Center for Scholars in Washington, D.C.; was Alistair Horne fellow of St Antony's College in Oxford. Stephen Bush; ( b. 1990) columnist and associate editor at the Financial Times; has written for The Guardian, The Daily Telegraph, The Jewish Chronicle, Jewish News, Times of Israel, The i Paper and New Statesman; runner-up in the Young Journalist of the Year awards category in Press Awards; was awarded Political Studies Association's Journalist of the Year award;was appointed to chair the Board of Deputies of British Jews' Commission on Racial Inclusivity in the Jewish Community. Barbara Charone author of authorised biography of Keith Richards; board member of Chelsea F.C.; journalist and music critic for the NME, Rolling Stone, Sounds magazine and Creem; public relations and press director at WEA; founded the agency MBC PR where clients include Madonna, Depeche Mode, Primal Scream, Robert Plant, Pearl Jam, Rod Stewart and Christina Aguilera as well as comedians David Walliams, Graham Norton and Russell Brand; won the Music Week Press Award in 2006 and 2009; The Guardian included her on list of "The 20 most powerful celebrity makers" as "Britain's most powerful music PR", citing her reviving of careers of Madonna and Neil Diamond and establishing Duffy and Mark Ronson. Charone is on Chelsea F.C.
Sources: en.wikipedia.org
A form of tofu may have been discovered during the Han dynasty (202 BC – AD 220), but it did not become a popular food in China until the Song dynasty (960–1279). In China, tofu was traditionally eaten at the graves of deceased relatives. Ghosts were said to have long since lost their chins and jaws, so only tofu was soft enough for them to eat. Before the advent of refrigeration in China, tofu was usually sold only in the winter because it did not spoil easily in cold weather. In the warmer months, once made, tofu would spoil if left for more than a day.
== Awards and honors == 2017, "From Discovery to Precision Medicine: Mass Spectrometry Through the Years and Beyond" at Pittcon 2017, a session focused on the contributions of Robert E. Finnigan 2008, Selected for "Legends of Environmental Chemistry" by American Chemical Society, ACS annual meeting, New York 1999, Instrumentation Hall of Fame (Charter Member) by Pittcon, American Chemical Society and Chemical Heritage Foundation 1994, Selected as a Pioneer in Development of Analytical Instrumentation by Pittsburgh Conference (Pittcon) and American Chemical Society 1980, Distinguished Service in Engineering, College of Engineering, University of Illinois 1975, Distinguished Alumni Award, Electrical and Computer Engineering Department, University of Illinois
It was only during the 1980s that a consensus among researchers was reached that these vessels can preserve as much as 30 to 40% of coronary blood flow to an otherwise-occluded blood vessel, and, while not capable of preventing ischemia in the event of high-output exercise, can nevertheless maintain aortic, pulmonic, and atrial blood pressure, redirect ST elevation into less serious ST depression in ischemia, and prevent infarction and symptoms of infarction, even in the case of complete left main coronary artery stenosis. The native collaterals are small vessels, with a narrow endothelial lining, a layer or two of smooth muscle, and a variable amount of elastic tissue. They are rarely if ever observed during angiography in the absence of severe ischemia (vessels less than 200 micrometers are not visible, generally), and only coronary stenosis, anemia, and exercise have experimentally been shown to cause transformation. Most observers agree that a 90% occlusion is necessary to bring about transformation in the absence of other factors, though a recent article suggests that they may appear as a result of coronary spasm in the absence of total occlusion (see below). Within ninety seconds of occlusion, the pressure gradient between the segment of the coronary vessel distal to the occlusion and the incipient collateral vessel precipitates damage to the internal elastic lamina, provoking an inflammatory response; monocytes and polycytes migrate to the vascular wall, which has, as a result of the occlusion, become permeable to the blood's cellular components.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.